---
title: "Bio-Techne Corporation (TECH.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TECH.US.md"
symbol: "TECH.US"
name: "Bio-Techne Corporation"
industry: "Life Sciences Tools and Services"
datetime: "2026-04-30T17:08:01.633Z"
locales:
  - [en](https://longbridge.com/en/quote/TECH.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TECH.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TECH.US.md)
---

# Bio-Techne Corporation (TECH.US)

## Company Overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.bio-techne.com](https://www.bio-techne.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-30T04:30:17.000Z

**Overall: C (0.41)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 22 / 63 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.64% |  |
| Net Profit YoY | -48.73% |  |
| P/B Ratio | 4.04 |  |
| Dividend Ratio | 0.62% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8127748519.40 |  |
| Revenue | 1215578000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.96% | C |
| Profit Margin | 6.67% | B |
| Gross Margin | 65.29% | A |
| Revenue YoY | 1.64% | C |
| Net Profit YoY | -48.73% | D |
| Total Assets YoY | -5.53% | D |
| Net Assets YoY | -3.25% | D |
| Cash Flow Margin | 307.57% | A |
| OCF YoY | 1.64% | C |
| Turnover | 0.47 | C |
| Gearing Ratio | 20.28% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Bio-Techne Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.64%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-48.73%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.04",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.62%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8127748519.40",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1215578000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.96%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "6.67%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "65.29%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1.64%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-48.73%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-5.53%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3.25%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "307.57%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "1.64%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.47",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "20.28%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 100.27 | 19/63 | 126.57 | 112.69 | 63.26 |
| PB | 4.04 | 38/63 | 4.95 | 4.43 | 4.03 |
| PS (TTM) | 6.69 | 46/63 | 7.86 | 7.15 | 6.64 |
| Dividend Yield | 0.62% | 6/63 | 0.62% | 0.56% | 0.52% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | B | B | C | B | B |
| 03 | Waters (WAT.US) | A | B | B | C | C | B |
| 04 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-22T04:00:00.000Z

Total Analysts: **14**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 64% |
| Overweight | 1 | 7% |
| Hold | 4 | 29% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 54.64 |
| Highest Target | 80.00 |
| Lowest Target | 65.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TECH.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TECH.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TECH.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TECH.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**